Kelsey R Thomas1, Katherine J Bangen1, Alexandra J Weigand1, Emily C Edmonds1, Christina G Wong1, Shanna Cooper1, Lisa Delano-Wood1, Mark W Bondi2. 1. From Veterans Affairs San Diego Healthcare System (K.R.T., K.J.B., A.J.W., E.C.E., C.G.W., S.C., L.D.-W., M.W.B.); Department of Psychiatry (K.R.T., K.J.B., A.J.W., E.C.E., C.G.W., S.C., L.D.-W., M.W.B.), University of California, San Diego, School of Medicine, La Jolla; and San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology (A.J.W.). 2. From Veterans Affairs San Diego Healthcare System (K.R.T., K.J.B., A.J.W., E.C.E., C.G.W., S.C., L.D.-W., M.W.B.); Department of Psychiatry (K.R.T., K.J.B., A.J.W., E.C.E., C.G.W., S.C., L.D.-W., M.W.B.), University of California, San Diego, School of Medicine, La Jolla; and San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology (A.J.W.). mbondi@ucsd.edu.
Abstract
OBJECTIVE: To determine the temporal sequence of objectively defined subtle cognitive difficulties (Obj-SCD) in relation to amyloidosis and neurodegeneration, the current study examined the trajectories of amyloid PET and medial temporal neurodegeneration in participants with Obj-SCD relative to cognitively normal (CN) and mild cognitive impairment (MCI) groups. METHOD: A total of 747 Alzheimer's Disease Neuroimaging Initiative participants (305 CN, 153 Obj-SCD, 289 MCI) underwent neuropsychological testing and serial amyloid PET and structural MRI examinations. Linear mixed effects models examined 4-year rate of change in cortical 18F-florbetapir PET, entorhinal cortex thickness, and hippocampal volume in those classified as Obj-SCD and MCI relative to CN. RESULT: Amyloid accumulation was faster in the Obj-SCD group than in the CN group; the MCI and CN groups did not significantly differ from each other. The Obj-SCD and MCI groups both demonstrated faster entorhinal cortical thinning relative to the CN group; only the MCI group exhibited faster hippocampal atrophy than CN participants. CONCLUSION: Relative to CN participants, Obj-SCD was associated with faster amyloid accumulation and selective vulnerability of entorhinal cortical thinning, whereas MCI was associated with faster entorhinal and hippocampal atrophy. Findings suggest that Obj-SCD, operationally defined using sensitive neuropsychological measures, can be identified prior to or during the preclinical stage of amyloid deposition. Further, consistent with the Braak neurofibrillary staging scheme, Obj-SCD status may track with early entorhinal pathologic changes, whereas MCI may track with more widespread medial temporal change. Thus, Obj-SCD may be a sensitive and noninvasive predictor of encroaching amyloidosis and neurodegeneration, prior to frank cognitive impairment associated with MCI.
OBJECTIVE: To determine the temporal sequence of objectively defined subtle cognitive difficulties (Obj-SCD) in relation to amyloidosis and neurodegeneration, the current study examined the trajectories of amyloid PET and medial temporal neurodegeneration in participants with Obj-SCD relative to cognitively normal (CN) and mild cognitive impairment (MCI) groups. METHOD: A total of 747 Alzheimer's Disease Neuroimaging Initiative participants (305 CN, 153 Obj-SCD, 289 MCI) underwent neuropsychological testing and serial amyloid PET and structural MRI examinations. Linear mixed effects models examined 4-year rate of change in cortical 18F-florbetapir PET, entorhinal cortex thickness, and hippocampal volume in those classified as Obj-SCD and MCI relative to CN. RESULT: Amyloid accumulation was faster in the Obj-SCD group than in the CN group; the MCI and CN groups did not significantly differ from each other. The Obj-SCD and MCI groups both demonstrated faster entorhinal cortical thinning relative to the CN group; only the MCI group exhibited faster hippocampal atrophy than CN participants. CONCLUSION: Relative to CN participants, Obj-SCD was associated with faster amyloid accumulation and selective vulnerability of entorhinal cortical thinning, whereas MCI was associated with faster entorhinal and hippocampal atrophy. Findings suggest that Obj-SCD, operationally defined using sensitive neuropsychological measures, can be identified prior to or during the preclinical stage of amyloid deposition. Further, consistent with the Braak neurofibrillary staging scheme, Obj-SCD status may track with early entorhinal pathologic changes, whereas MCI may track with more widespread medial temporal change. Thus, Obj-SCD may be a sensitive and noninvasive predictor of encroaching amyloidosis and neurodegeneration, prior to frank cognitive impairment associated with MCI.
Authors: Bruce Fischl; David H Salat; Evelina Busa; Marilyn Albert; Megan Dieterich; Christian Haselgrove; Andre van der Kouwe; Ron Killiany; David Kennedy; Shuna Klaveness; Albert Montillo; Nikos Makris; Bruce Rosen; Anders M Dale Journal: Neuron Date: 2002-01-31 Impact factor: 17.173
Authors: Katherine J Bangen; Alexandra J Weigand; Kelsey R Thomas; Lisa Delano-Wood; Lindsay R Clark; Joel Eppig; Madeleine L Werhane; Emily C Edmonds; Mark W Bondi Journal: Neuropsychology Date: 2019-03-21 Impact factor: 3.295
Authors: Lawrence S Honig; Bruno Vellas; Michael Woodward; Mercè Boada; Roger Bullock; Michael Borrie; Klaus Hager; Niels Andreasen; Elio Scarpini; Hong Liu-Seifert; Michael Case; Robert A Dean; Ann Hake; Karen Sundell; Vicki Poole Hoffmann; Christopher Carlson; Rashna Khanna; Mark Mintun; Ronald DeMattos; Katherine J Selzler; Eric Siemers Journal: N Engl J Med Date: 2018-01-25 Impact factor: 91.245
Authors: Anne Maass; Samuel N Lockhart; Theresa M Harrison; Rachel K Bell; Taylor Mellinger; Kaitlin Swinnerton; Suzanne L Baker; Gil D Rabinovici; William J Jagust Journal: J Neurosci Date: 2017-11-30 Impact factor: 6.167
Authors: Theresa M Harrison; Renaud La Joie; Anne Maass; Suzanne L Baker; Kaitlin Swinnerton; Laura Fenton; Taylor J Mellinger; Lauren Edwards; Julie Pham; Bruce L Miller; Gil D Rabinovici; William J Jagust Journal: Ann Neurol Date: 2019-01-17 Impact factor: 10.422
Authors: S M Landau; B A Thomas; L Thurfjell; M Schmidt; R Margolin; M Mintun; M Pontecorvo; S L Baker; W J Jagust Journal: Eur J Nucl Med Mol Imaging Date: 2014-03-20 Impact factor: 9.236
Authors: Manu S Goyal; Brian A Gordon; Lars E Couture; Shaney Flores; Chengjie Xiong; John C Morris; Marcus E Raichle; Tammie L-S Benzinger; Andrei G Vlassenko Journal: Neurobiol Aging Date: 2020-09-01 Impact factor: 4.673
Authors: Kelsey R Thomas; Jessica R Osuna; Alexandra J Weigand; Emily C Edmonds; Alexandra L Clark; Sophia Holmqvist; Isabel H Cota; Christina E Wierenga; Mark W Bondi; Katherine J Bangen Journal: J Cereb Blood Flow Metab Date: 2020-07-02 Impact factor: 6.200
Authors: Nikki H Stricker; Emily S Lundt; Sabrina M Albertson; Mary M Machulda; Shehroo B Pudumjee; Walter K Kremers; Clifford R Jack; David S Knopman; Ronald C Petersen; Michelle M Mielke Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Shehroo B Pudumjee; Emily S Lundt; Sabrina M Albertson; Mary M Machulda; Walter K Kremers; Clifford R Jack; David S Knopman; Ronald C Petersen; Michelle M Mielke; Nikki H Stricker Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Kristina M Gicas; William G Honer; Robert S Wilson; Patricia A Boyle; Sue E Leurgans; Julie A Schneider; David A Bennett Journal: Neurology Date: 2020-11-03 Impact factor: 9.910